On International Clinical Trials Day, we're highlighting the importance of clinical trials, without which we would have no new medicines or vaccines. Dr Janet Valentine explains below. #ICTD @nihr.bsky.social @hralatest.bsky.social @mhragovuk.bsky.social www.youtube.com/watch?v=PaqV...

Delighted to welcome a new @plaidcymru.bsky.social government under @rhunapiorwerth.bsky.social's leadership. We will continue our work to support equitable access to innovation, drive health & economic ambitions to deliver better health outcomes for people in Wales. www.abpi.org.uk/publications...

📋 New blog from ABPI's Sophie Caseby unpacking the latest EFPIA W.A.I.T. Indicator report. England ranks 7th in Europe for access to newly approved medicines overall — but 14th for cancer treatments. What's driving the gap, and what needs to change? 👇 www.abpi.org.uk/media/blogs/...

Medicines supply issues are relatively rare, but when they happen, they can have a serious impact on patients. Our new report sets out how to improve the supply chain to anticipate risks and respond quickly when disruption occurs. Read more: www.abpi.org.uk/publications...

Decentralised or hybrid clinical trials can bring research closer to home - boosting access & inclusion. A new @acmedsci.bsky.social report, supported by us + @nihr.bsky.social shows how to encourage more of these trials: choice, trust & clearer guidance. acmedsci.ac.uk/file-downloa...

We are celebrating World Immunization Week🎉 Vaccines have safely protected people, families, and communities for generations and as part of our free learning resources for schools you can find out more about the importance of vaccinations with Ellie. www.abpischools.org.uk/topics/ellie...

The panel discussed how co-creation between industry, academia, government and the NHS is essential to remove barriers and expand access to research. #ABPIconf26

Next up is our clinical trials panel! Improvements in regulatory performance, alongside the UK’s unique health data assets, are strengthening the environment for commercial and non commercial clinical trials. For industry, the priorities are clear: predictability, accuracy and speed. #ABPIconf26

The ABPI Exam offers qualifications for industry personnel to have the understanding they need to promote medicines ethically. Each year, we recognise the candidate who has achieved the highest grade. Congratulations to Pedro Figueiredo Aparicio from Johnson & Johnson Innovative Medicine UK! 🎉👏🏆

Panellists pointed to the value of bringing together industry, government, academia and the health system to unlock the UK’s full potential. #ABPIconf26

A strong start to today’s growth panel on where the UK can win globally. The discussion pointed to a clear opportunity for the UK at the intersection of life sciences and AI, with healthcare seen as one of the most promising settings for innovation to flourish. #ABPIconf26

Opening, our Chief Executive said the UK is starting to choose growth, innovation and faster patient access to medicines. We've long known of problems in the UK - 102 medicines launched in the US have not launched in European markets, vs 15 the other way round.

Our annual conference is underway! We’re looking forward to a full agenda discussing how best to position the UK as a leading place to research, develop and use innovative medicines. #ABPIconf26

Vaccination is one of the most effective ways to protect people’s health, preventing illness and reducing pressure on the NHS. Find out more about the value of vaccination: www.abpi.org.uk/value-and-ac... #Vaccination #EIW2026 #WIW2026

Vaccine Engagement Day 2026 has arrived! 🎉 Let’s come together to #CelebrateVaccines by sharing information and enhancing public awareness about vaccines!🌟 Discover how you can participate: vist.ly/4v2vi

The use of NHS data has the potential to transform commercial clinical trials in the UK by making recruitment faster, more efficient, and participation more inclusive. Read our latest report: “Globally competitive UK-wide data-enabled clinical trials: the time is now www.abpi.org.uk/publications...

NHS–industry partnerships are essential for high-quality healthcare. But they can mean conflicts of interest. Read our blog that explains the safeguards on this - including our strict Code of Practice & independent regulation. 📖 Read more: www.abpi.org.uk/media/blogs/...

Strengthening Northern Ireland’s health and economy through life sciences leadership. 🧬🔬💊💉 Read our colleague Marion Laverty's piece on the ABPI's work in Northern Ireland for @hiranihealth.bsky.social hira-ni.com/improving-he...

🚨New video: Understanding Disclosure UK Learn how the pharmaceutical industry’s transparency database works, and how it forms part of wider frameworks for managing conflicts of interest. Watch below ⬇️ www.youtube.com/watch?v=pT5e...

Partnerships between the NHS and the pharmaceutical industry play an important role in improving patient outcomes. Dr Amit Aggarwal sets out why these relationships matter and the safeguards to ensure transparency and manage conflicts of interest. www.abpi.org.uk/media/blogs/...

NEW: Our Medical Director Dr Amit Aggarwal's comment on NHS-industry partnerships and the safeguards in place to manage conflicts of interest. Companies may also benefit from partnerships, but the priority has to be to put the NHS & patients first. www.abpi.org.uk/media/blogs/...

Our colleague Brian Duggan spoke at the APPG for Black Health event on increasing diversity in clinical trials @paulettehamiltonmp.bsky.social Lack of diversity in clinical trials is a huge issue that has real consequences for health. Read his reflections: abpi.org.uk/media/blogs/...

This @careersweek.bsky.social we're showcasing the diverse range of roles within the pharmaceutical industry. If you’re exploring your next step or curious about what a career in the industry can look like visit our job cases studies: www.abpi.org.uk/careers/job-... www.youtube.com/watch?v=uaoE...

Equity in rare diseases means equal access to diagnosis, treatment, health and social care, and the opportunity to fully participate in society. Read the @geneticallianceuk.bsky.social report on this: geneticalliance.org.uk/wp-content/u... #RareDiseaseDay #RareEquity

For #RareDiseaseDay we’re sharing Alan’s amazing journey with ataxia - he founded Ataxia and Me to raise awareness and connect people around the world. 🌍 Thanks to @geneticallianceuk.bsky.social for championing every voice in the rare disease community. 💪 abpi.org.uk/media/blogs/...

For Emily Reuben, CEO, Duchenne UK, equity in rare disease means removing barriers to children getting new treatments. They call for a children’s health technology assessment pathway with achievable evidence standards. #RareDiseaseDay @geneticallianceuk.bsky.social www.abpi.org.uk/rare-disease...

In a guest blog for #RareDiseaseDay, Laurence Woollard reflects on what haemophilia gene therapy teaches us about equity, access & adoption of advanced therapies in the NHS. @geneticallianceuk.bsky.social @cgtcatapult.bsky.social Read it here: www.abpi.org.uk/media/blogs/...

🚨New: Blog from our colleague Dan O'Connor for #RareDiseaseDay: Prevention can be the most powerful treatment of all. A timely read highlighting why equity & prevention are vital. @geneticallianceuk.bsky.social 🔗 Read more: www.abpi.org.uk/media/blogs/... #RareDiseaseDay2026 #rarequity

Our colleague Dan O'Connor attended the packed @geneticallianceuk.bsky.social Rare Disease Day event yesterday. 🧑‍🤝‍🧑 Great to see so many people calling for equity for rare diseases. Download the @geneticallianceuk.bsky.social's advocacy pack 👉http://bit.ly/4rp81yB #rarequity #RareDiseaseDay

✨Meet Anna! She lives with rare bone condition hypophosphatasia (HPP), but nothing stops her. On #RareDiseaseDay, we celebrate Anna and every person with a rare disease. @geneticallianceuk.bsky.social Read her story: www.abpi.org.uk/media/blogs/...

This year’s @geneticallianceuk.bsky.social #RareDiseaseDay focuses on equity and why it matters more than ever. Chris Walden, CEO of @cancer52org.bsky.social, reflects on what equity means in practice. Read the full Q&A on the ABPI rare disease hub: 👉https://www.abpi.org.uk/rare-diseases/

The theme of this year's #RareDiseaseDay is equity. In our Q&A, Rick Thompson, CEO of Beacon: for rare diseases reflects on what equity means for him and his organisation. Read more at the ABPI's rare disease hub www.abpi.org.uk/rare-diseases/ @rarediseaseday.bsky.social

Many medicines entering clinical trials fail because pre-clinical testing does not accurately predict effects in humans. A key reason? A gap between some 'pre-clinical models' and industry needs. A new ABPI/@nc3rs.bsky.social review sets out how to close this gap. abpi.org.uk/publications...

We are delighted to publish a report with @abpi.bsky.social that examines the UK landscape in human relevant in vitro models. It will help inform wider policy, funding and infrastructure requirements to accelerate translation and deliver benefits for pharmaceutical R&D. nc3rs.org.uk/news/landsca...

🚨The UK has a major opportunity to accelerate the development of new medicines 🧬 A new report from ABPI & @nc3rs.bsky.social shows how to help pre-clinical models turn potential medicines into real-world treatments. 🧷 www.abpi.org.uk/media/news/2...

Thinking about a career in the pharmaceutical industry? It's #NationalApprenticeshipWeek & we are sharing the different routes into the industry, including apprenticeships, & the opportunities they open up. Take a look: www.abpi.org.uk/careers/job-... www.youtube.com/watch?v=fxXR... #NAW2026

Despite continued advances in cancer research, UK patients can access fewer cancer medicines through the NHS than patients in comparable European countries. Find out more about improving access to cancer medicines: www.abpi.org.uk/publications...

What drives company decisions on new medicine launches and UK investment? The findings of ABPI's 2025 Medicines Impact and Investment Survey track how UK policy conditions influence companies' investment and prioritisation decisions for medicines launches. www.abpi.org.uk/media/blogs/...

At the moment, NHS patients with blood cancer can only access half of the approved medicines for their condition. Reviewing how these medicines are valued is a first step to giving UK patients the treatments that could save or prolong their lives. Learn more: www.ourcommongoal.org.uk/blood-cancer/

New breast cancer treatments can extend patients’ lives, yet some remain unavailable in parts of the UK. Rethinking the way such medicines are valued and approved is a crucial first step in increasing access to life-extending care for more UK patients. Find out more: www.ourcommongoal.org.uk

It's time to emphasise the economics in health economics. Victoria Jordan discusses the health economics of the UK-US Economic Prosperity Deal and plans increase NICE's baseline threshold use, the first change since its introduction in the early 2000s. abpi.uksouth01.umbraco.io/media/blogs/...

Alzheimer’s devastates the lives of patients and their families, costing billions in care. New treatments that can slow the disease’s progression in its early stages have recently been licensed in the UK - yet NHS patients are still being denied access. Find out more: www.ourcommongoal.org.uk

#ABSWawards As we prepare for the ABSW Awards 2026, we want to thank the partners whose continued support helps us celebrate excellence in science journalism... @abpi.bsky.social Dr Katharine Giles Fund @royalsociety.org AlphaGalileo Want to be an ABSW Awards partner? Find how👉 zurl.co/gPGgo

Publication of 'A Common Understanding 2025' marked an important milestone for collaborative working in Scotland earlier this year. It shows how partnership across industry, academia & the NHS can improve patient care & drive innovation. www.gov.scot/publications...

We’re proud to share our guidance on creating successful NHS-industry partnerships in Northern Ireland’s health & social care system. Developed with @niconfederation.bsky.social, it’s designed to accelerate innovation and improve patient outcomes. www.abpi.org.uk/publications...

Earlier this year we launched joint guidance with @welshnhsconfed.bsky.social to help the NHS and industry work together more confidently, transparently & effectively. 📘 Download here to create successful partnerships for your organisation www.nhsconfed.org/publications... #PartnershipWorking

NHS–industry partnership guidance is now in place across all 4 UK nations. Developed with @nhsconfed.org, @welshnhsconfed.bsky.social, @niconfederation.bsky.social, and the Scottish Government, these frameworks support better outcomes for patients ⬇️ Find out more at www.abpi.org.uk/partnerships/

The VPAG payment rate for newer medicines will be 14.5% in 2026. With the addition of the 1% investment programme, the total rebate for newer medicines in 2026 will be 15.5% of revenues. www.abpi.org.uk/media/news/2...

There’s been a drop in ppl participating in interventional industry clinical trials 📉 There are many potential reasons for this - lots of action underway to fix it 🔧 We're proposing further measures in our latest report. abpi.org.uk/publications... @nihr.bsky.social

Did you know the 150-day target for setting up industry clinical trials has 3 parts? ⏱️🧪 We’re on track with some — but others need work. Read our latest report: www.abpi.org.uk/publications... @nihr.bsky.social